| Quantity: | |
|---|---|
Clinically relevant – Scopolamine-induced dry eye mimics human condition by reducing tear production via muscarinic receptor blockade.
Quantifiable endpoints – Tear volume measurement (phenol red thread test or Schirmer test), corneal fluorescein staining score, Harderian gland histopathology (H&E), ocular surface imaging.
Well-characterized model – Widely used for evaluating tear substitute formulations, anti-inflammatory drugs, and lacrimal gland stimulants.
Translational value – Ideal for testing tear secretagogues, lubricants, cyclosporine A, lifitegrast, and anti-inflammatory biologics.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Representative data from our Scopolamine Induced Mouse Dry Eye model:
SCOP Induced Xerophthalmia Model in Mice
• Efficacy testing of tear substitutes, lubricants, and ocular surface protectants
• Evaluation of anti-inflammatory drugs (cyclosporine A, lifitegrast, corticosteroids) for dry eye disease
• Target validation for lacrimal gland function and tear secretion pathways
• Biomarker discovery (tear osmolarity, inflammatory cytokines)
• IND-enabling pharmacology and toxicology studies
Parameter | Specification |
Species/Strain | BALB/c mouse (other strains available upon request) |
Induction method | Subcutaneous or intraperitoneal injection of scopolamine (SCOP), 4 times daily for 5–10 days |
Study duration | 7–14 days (induction + treatment phase) |
Key endpoints | Tear volume (phenol red thread test), corneal fluorescein staining score, Harderian gland histopathology (H&E), ocular surface imaging, optional: tear cytokine levels, goblet cell density |
Data package | Raw data, analysis reports, clinical photographs, histology slides, bioinformatics (optional) |
Q: How does scopolamine induce dry eye?
A: Scopolamine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic input to lacrimal glands, reducing tear secretion and altering tear film composition.
Q: What are the key similarities with human dry eye?
A: The model exhibits decreased tear production, corneal epithelial damage (fluorescein staining), and Harderian gland inflammation, closely resembling human aqueous-deficient dry eye.
Q: Can this model be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different dosing frequencies, combination with environmental stress)?
A: Absolutely. Our scientific team tailors scopolamine dosing regimens, treatment schedules, and endpoint analyses to your specific drug candidate.